U.S. FDA to review Teva and Celltrion's cancer biosimilar drug

JERUSALEM (Reuters) - Teva Pharmaceutical Industries and South Korea's Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.